The little-known big problem

This site is intended only for healthcare professionals residing in Singapore

Log Out

Our medicines

Therapy areas

Explore content

Events

Materials

Videos

Let’s connect

Medical Information

Think Fungus, Save Lives

MDR Gram-negative Infections

CAP and cSSTI Infections

The little-known big problem

What are MBLs?

MBL Patient Profiles

Metallo-β-lactamases (MBLs): The little-known big problem.

Antimicrobial resistance (AMR), including among Gram-negative bacteria, is now officially recognized as a global crisis.^1,6

Multidrug-resistant (MDR) Gram-negative bacteria, including MBL-producing bacteria, have been highlighted as a critical priority group by the WHO and are a major public health concern due to limited treatment options.^7-10

Putting MBLs under the spotlightPutting

Putting MBLs under the spotlight

MBLs are spreading globally and alarmingly fast.^1,2,3 There is an urgent need to tackle problematic carbapenemases and slow their spread in difficult-to-treat organisms,^1,4,5 with the ultimate aim of helping to prevent avoidable morbidity and mortality.

MBLs can be expressed by Enterobacterales and S. maltophilia, among other bacteria.^2,14

Up to 55.3%^11-13

mortality rate associated with

MBL-producing Enterobacterales

vs 14.7% for controls*

Up to 77%¹⁴

mortality rate reported for S.maltophilia
Pneumonia+

DID YOU KNOW?

MBLs account for the majority of the ‘Big Five’ carbapenemases.

Why are MBLs an urgent problem?

Do you want to discover and understand more about MBLs?
Click to hear Dr. Luke Moore explain what MBLs are and to learn about the ‘Big Five’ carbapenemases.

Understanding MBLs

Are you aware of the risk factors for MBL-producing pathogens?
Learn about key patient risk factor associated with infections caused by MBL-producing enterobacterales.

View patient profiles

In-hospital mortality among 38 cases with New Delhi metallo-β-lactamase (NDM)-1-producing Enterobacterales vs 68 controls (adjusted for comorbid disease). Klebsiella pneumoniae (K. pneumoniae) was the most common NDM-1-producer. Specimens collected 48 hours after admission.¹³
+Rates reported across six different studies with different patient types. Highest rates are observed among patients with cancer and concomitant bacteraemia¹⁴

Henderson J, et al. J Hosp Infect 2020;104:12–19

Boyd SE, et al. Antimicrob Agents Chemother 2020;64:e00397-20.

Wu W, et al. Clin Microbiol Rev 2019;32:e00115-18.

Nordmann P, et al. Emerg Infect Dis 2011;17:1791–8.

Bonomo RA, et al. Clin Infect Dis 2018;66:1290–7

Antimicrobial Resistance Collaborators. Lancet. 2022;399(10325):629–655.

2023 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2024. Available at:https://iris.who.int/bitstream/handle/10665/376944/9789240094000-eng.pdf?sequence=1. Last accessed March 2025.

Timsit JF, et al. Antibiotics (Basel). 2022;11(2):144.

BSAC. Antimicrobial stewardship: From principles to practice. 2018. Available at: http://www.bsac.org.uk/antimicrobialstewardship-from-principles-to-practice-e-book/ebook-download/. Last accessed March 2025.

Khan AU, et al. BMC Microbiol. 2017;17(1):101.

Daikos GL, et al. Antimicrob Agents Chemother. 2009;53(5):1868-73.

Hayakawa K, et al. J Antimicrob Chemother. 2020;75(3):697-708.

De Jager P, et al. PLoS One. 2015;10(4):e0123337.

Looney WJ, et al. Lancet Infect Dis. 2009;9(5):312-23.

Mojica MF, et al. Clin Microbiol Rev 2022;35:e00015-21

Tan X, et al. Infect Drug Resist 2021;14:125–142

References

PP-UNP-SGP-0302/01APR2026

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.